Microbot Medical (NASDAQ:MBOT) Cut to "Strong Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Microbot Medical (NASDAQ:MBOT) from a "sell" to a "strong sell" in a report issued Saturday.
• Analyst opinions remain mixed — one Strong Buy, two Buy, one Hold and one Sell — leaving a MarketBeat average rating of "Moderate Buy" and a consensus target price of $7.50.
• MBOT opened at $2.10 with a market cap of $141 million and a 12‑month range of $1.60–$4.67, and it reported quarterly EPS of ($0.04), beating estimates by $0.02.

Microbot Medical (NASDAQ:MBOT - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Saturday.

Several other research analysts also recently issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Microbot Medical in a report on Friday, April 10th. HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Microbot Medical in a research report on Tuesday, April 14th. Finally, B. Riley Financial initiated coverage on Microbot Medical in a report on Tuesday, February 10th. They issued a "buy" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Microbot Medical currently has an average rating of "Moderate Buy" and a consensus target price of $7.50.

Microbot Medical Trading Up 0.5%

MBOT stock opened at $2.10 on Friday. The firm has a 50-day moving average price of $2.41 and a 200-day moving average price of $2.25. Microbot Medical has a 12 month low of $1.60 and a 12 month high of $4.67. The stock has a market capitalization of $141.04 million, a P/E ratio of -7.24 and a beta of 1.06.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings data on Sunday, March 22nd. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. As a group, equities analysts predict that Microbot Medical will post -0.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Microbot Medical

Large investors have recently modified their holdings of the business. Private Advisor Group LLC acquired a new position in shares of Microbot Medical during the first quarter worth $54,000. Caitong International Asset Management Co. Ltd acquired a new stake in Microbot Medical in the fourth quarter valued at $65,000. Virtu Financial LLC acquired a new stake in Microbot Medical in the fourth quarter valued at $117,000. Invesco Ltd. bought a new position in Microbot Medical during the 4th quarter worth $49,000. Finally, XTX Topco Ltd bought a new position in Microbot Medical during the 4th quarter worth $63,000. Institutional investors own 16.30% of the company's stock.

Microbot Medical Company Profile

Microbot Medical Inc NASDAQ: MBOT is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.